Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Helsinn Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT\u00ae\/ALOXI\u00ae and AKYNZEO\u00ae in Russia and CIS region","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Pharma Submits Application for Additional Dosage and Administration of 5-HT3 Receptor Antagonist Aloxi\u00ae for Pediatric Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn and Fosun Pharma Sign Exclusive License and Distribution Agreements For Aloxi\u00ae, Akynzeo\u00ae Oral, NEPA IV and Anamorelin in Mainland China, Hong Kong SAR and Macau SAR","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Helsinn Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Farma Mondo Group and Helsinn Sign Exclusive Partnership To Commercialize AKYNZEO\u00ae In The Baltic Region","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn and Immedica Enter Exclusive Partnership for Commercialisation of Cancer Supportive Care Products in Core European Markets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Announces Presentation On CINV Trial at European Society for Medical Oncology (ESMO) Asia","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Publishes Results From A Secondary Analysis Of A Phase 3 Trial In Patients With CINV Helsinn Publishes Results From A Secondary Analysis Of A Phase 3 Trial In Patients With CINV","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Announces Publication of New Data Evaluating Impact Of NEPA (netupitant\/palonosetron) On Hospital Costs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Palonosetron

    Menu

    Palonosetron

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Helsinn Advanced Synthesis

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Helsinn Announces Publication of New Data Evaluating Impact Of NEPA (netupitant/palonosetron) On Hospital Costs

              Details:

              Akynzeo is a combination of netupitant, a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors and palonosetron, a 5-HT3 receptor antagonist with a strong binding affinity for this receptor. It is indicated for nausea due to cancer chemotherapy.

              Lead Product(s): Netupitant,Palonosetron

              Therapeutic Area: Gastroenterology Product Name: Akynzeo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Helsinn Advanced Synthesis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Helsinn and Immedica Enter Exclusive Partnership for Commercialisation of Cancer Supportive Care Products in Core European Markets

              Details:

              Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.

              Lead Product(s): Netupitant,Palonosetron

              Therapeutic Area: Gastroenterology Product Name: Akynzeo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Immedica Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Helsinn Advanced Synthesis

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Helsinn Publishes Results From A Secondary Analysis Of A Phase 3 Trial In Patients With CINV Helsinn Publishes Results From A Secondary Analysis Of A Phase 3 Trial In Patie...

              Details:

              AKYNZEO (Netupitant) is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.

              Lead Product(s): Netupitant,Palonosetron

              Therapeutic Area: Gastroenterology Product Name: Akynzeo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Helsinn Advanced Synthesis

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Helsinn Announces Presentation On CINV Trial at European Society for Medical Oncology (ESMO) Asia

              Details:

              Akynzeo is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.

              Lead Product(s): Netupitant,Palonosetron

              Therapeutic Area: Gastroenterology Product Name: Akynzeo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              FarmaMondo

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Farma Mondo Group and Helsinn Sign Exclusive Partnership To Commercialize AKYNZEO® In The Baltic Region

              Details:

              Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO® in Estonia and Latvia. AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adults.

              Lead Product(s): Netupitant,Palonosetron

              Therapeutic Area: Gastroenterology Product Name: Akynzeo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Helsinn Group

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership November 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Fosun Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Helsinn and Fosun Pharma Sign Exclusive License and Distribution Agreements For Aloxi®, Akynzeo® Oral, NEPA IV and Anamorelin in Mainland China, Hong Kong SAR and Macau S...

              Details:

              Helsinn will grant Fosun an exclusive license to distribute, promote and sell the following products in the aforesaid territory: Aloxi (Palonosetron hydrochloride), Akynzeo (Netupitant and Palonosetron hydrochloride) and NEPA (Fosnetupitant and Palonosetron hydrochloride).

              Lead Product(s): Palonosetron

              Therapeutic Area: Gastroenterology Product Name: Aloxi

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Helsinn Advanced Synthesis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Taiho Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Taiho Pharma Submits Application for Additional Dosage and Administration of 5-HT3 Receptor Antagonist Aloxi® for Pediatric Patients

              Details:

              Aloxi® has demonstrated its efficacy in delayed nausea and vomiting where available agents have hitherto provided insufficient effects.

              Lead Product(s): Palonosetron

              Therapeutic Area: Gastroenterology Product Name: Aloxi

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Berlin Chemie

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region

              Details:

              Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.

              Lead Product(s): Fosnetupitant Chloride,Palonosetron

              Therapeutic Area: Gastroenterology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Helsinn Group

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY